Abstract-We previously conducted genome-wide association meta-analysis of systolic blood pressure, diastolic blood pressure, and hypertension in 29 136 people from 6 cohort studies in the Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium. Here we examine associations of these traits with 30 gene regions encoding known antihypertensive drug targets. We find nominal evidence of association of ADRB1, ADRB2, AGT, CACNA1A, CACNA1C, and SLC12A3 polymorphisms with 1 or more BP traits in the Cohorts for Heart and Aging Research in Genomic Epidemiology genome-wide association meta-analysis. We attempted replication of the top meta-analysis single nucleotide polymorphisms for these genes in the Global BPgen Consortium (nϭ34 433) and the Women's Genome Health Study (nϭ23 019) and found significant results for rs1801253 in ADRB1 (Arg389Gly), with the Gly allele associated with a lower mean systolic blood pressure (␤: 0.57 mm Hg; SE: 0.09 mm Hg; meta-analysis: Pϭ4.7ϫ10 Ϫ10 ), diastolic blood pressure (␤: 0.36 mm Hg; SE: 0.06 mm Hg; meta-analysis: Pϭ9.5ϫ10 Ϫ10 ), and prevalence of hypertension (␤: 0.06 mm Hg; SE: 0.02 mm Hg; meta-analysis: Pϭ3.3ϫ10 Ϫ4 ). Variation in AGT (rs2004776) was associated with systolic blood pressure (␤: 0.42 mm Hg; SE: 0.09 mm Hg; meta-analysis: Pϭ3.8ϫ10 Ϫ6 ), as well as diastolic blood pressure (Pϭ5.0ϫ10 Ϫ8 ) and hypertension (Pϭ3.7ϫ10 Ϫ7 ). A polymorphism in ACE (rs4305) showed modest replication of association with increased hypertension (␤: 0.06 mm Hg; SE: 0.01 mm Hg; meta-analysis: Pϭ3.0ϫ10 Ϫ5 ). Two loci, ADRB1 and AGT, contain single nucleotide polymorphisms that reached a genome-wide significance threshold in meta-analysis for the first time. Our findings suggest that these genes warrant further studies of their genetic effects on blood pressure, including pharmacogenetic interactions. (Hypertension. 2011;57:903-910.) • Online Data Supplement Key Words: drug target Ⅲ genome-wide Ⅲ SNP Ⅲ hypertension Ⅲ blood pressure E levated blood pressure (BP) is a critical risk factor for cardiovascular diseases, 1 and BP control in hypertensive individuals is an effective intervention for reducing cardiovascular disease risk. Hundreds of compounds representing multiple drug classes have been approved for treatment of hypertension. Achieving BP control in patients often requires multiple medications and trial-and-error switching of drug classes to achieve control. This suggests that interindividual differences in BP and in response to treatment may be influenced by genetic variation or environmental or other nongenetic factors.
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We recently completed a genome-wide association study (GWAS) and meta-analyses of systolic BP (SBP), diastolic BP (DBP), and hypertension in 29 136 individuals from 6 population-based cohorts of European ancestry in the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium, identifying and replicating novel BP loci at genome-wide significance levels. 2 Although GWASs have been successful in identifying new genes with common variants that exhibit small effects on BP, standard methods of analysis ignore all a priori information about specific genes. The strict requirements for controlling the occurrence of false-positives in such an "unbiased" approach lead to severe multiple testing corrections, whereby true-positive associations will be missed, particularly when replication resources are limited.
Examining subsets of GWAS associations based on a priori hypotheses is one way to identify genes of interest for further investigation 3 while paying a smaller penalty for multiple testing. Evidence from lipid GWASs and candidate gene studies indicates that some polymorphisms in drug target genes (eg, HMGCR and APOE) are associated with main effects on lipids, as well as effects on drug response. 4, 5 We hypothesized that GWAS approaches have missed some true BP association signals in antihypertensive drug target genes. We identified 30 drug target genes, including the targets of ␣-blockers, angiotensin-converting enzyme (ACE) inhibitors, ␤-blockers, angiotensin-receptor blockers, calcium-channel blockers, diuretics, and vasodilators, and analyzed single nucleotide polymorphisms (SNPs) in these gene regions for association with BP and hypertension.
Methods

Description of Cohorts, Participants, Genotypes, and Phenotypes
The CHARGE consortium cohorts, their genotyping, SNP imputation, 6 and BP and hypertension GWASs have been described previously. 2 Participants underwent standardized resting seated BP readings (means of 2 repeated measures used in analysis) and had GWAS results available (nϭ29 136). BP readings from the first examination attended were used. Hypertension was defined as SBP Ն140 mm Hg, DBP Ն90 mm Hg, or drug treatment for hypertension at BP assessment.
The Global BPgen Consortium (GBPG) included 17 cohorts of European ancestry with either population-based designs or controls drawn from case-control designs. 7 In most participants, BP analysis was based on the mean of 2 resting sitting measurements. 7 The Women's Genome Health Study population sample with BP and hypertension data consisted of 23 019 female health professionals of European descent Ն45 years of age at enrollment, free of cardiovascular disease or other major chronic illnesses, with GWAS and genotyping described previously. 8 BP was determined by selfreport in ranges (see the online Data Supplement, available at http://hyper.ahajournals.org), with the midpoint of these ranges used in analyses, and hypertension defined as above.
For individuals in CHARGE who were taking antihypertensive medication, we added 10/5 mm Hg to the observed SBP and DBP; for those in GBPG we added 15/10 mm Hg. Association results for different treatment adjustments were highly correlated in CHARGE (Table S1 , available in the online Data Supplement at http:// 
Discovery in CHARGE and Replication in GBPG/Women's Genome Health Study
Within each cohort, regression models for BP phenotypes were fit adjusting for sex, age, age squared, and body mass index. Genomic control () parameter values 9 were calculated and applied to account for within-study heterogeneity. Meta-analyses of the SNP-trait association estimates were inverse-variance weighted and reflect the combination of additive model analyses from the cohorts. 2 We identified a priori 30 candidate genes that code for proteins that are direct targets of antihypertensive drugs based on general knowledge and DrugBank (www.drugbank.ca), a database of human drug target genes. 10 We analyzed all of the CHARGE BP/hypertension associations within 60 kb of each target gene and applied a resampling-based test (Reference 11, see Figure S1 , available in the online Data Supplement at http://hyper.ahajournals.org). To augment SNPs for replication, we additionally selected SNPs at a PϽ1/(the number of SNPs tested). SNPs selected for replication are in bold in Table S2 (available in the online Data Supplement at http://hyper.ahajournals.org).
For selected gene regions, we examined the most significant CHARGE SNP-trait association for the same trait in GBPG and Women's Genome Health Study (WGHS). Replication was defined a priori as allelic association in the same direction as in CHARGE (thresholds: SBP, PϽ8.3ϫ10
Ϫ3 ). We also conducted meta-analysis to provide estimates comparable to GWAS thresholds. We used SNAP 12 to identify SNPs creating a protein change or (based on HapMap populations) in linkage disequilibrium (LD) with protein-changing variants or SNPs with previous associations with SBP, DBP, or hypertension.
Results
For 30 regions that encode antihypertensive drug targets, the single strongest SNP associations for SBP, DBP, and hypertension in/near each drug target gene for the initial CHARGE analysis are in Table S2 , along with the number of SNPs tested within each gene region. The most significant SNP association among the drug target genes tested in CHARGE was rs1985579 in CACNA1A with SBP (Pϭ2.6ϫ10 Ϫ5 ). Using resampling to account for multiple SNPs per locus, 2 significant SNP associations were identified for SBP (in ADRB1 and CACNA1A), 4 for DBP (in ADRB1, AGT, CACNA1A, and SLC12A3), and 4 for hypertension (in ADRB2, AGT, CACNA1C, and CACNA1H). At a less restrictive cutoff of PϽ1/(the number of SNPs tested in/near a gene), 11 additional SNPs in 9 genes were selected (ACE, ADRB2, AGT, CA1, CACNA1C, MME, REN, SCNN1A, and SLC9A1), for a total of 19 SNPs in 13 genes selected for replication. Two genes (CACNA1H and MME) were dropped from replication because their most associated SNPs had poor imputation in Ն2 groups, and attempts to find satisfactory surrogate SNPs in LD were unsuccessful.
For SBP we replicated associations for variants in ADRB1 and AGT (Table 1 ). In ADRB1 the minor allele of rs1801253 (nonsynonymous Arg389Gly) was associated with decreased SBP (replication: Pϭ7.3ϫ10
Ϫ7 ; meta-analysis: ␤ (units as mm Hg) Ϫ0.57, SE 0.09, Pϭ4.7ϫ10 Ϫ10 ), and in AGT the minor allele of rs2004776 was associated with increased SBP (replication: Pϭ2.8ϫ10 Ϫ5 ). We also replicated associations for ADRB1 and AGT with DBP ( Table 2 ). The minor allele of rs1801253 in ADRB1 was associated with decreased DBP (replication: Pϭ2.5ϫ10
Ϫ7 ; meta-analysis: ␤ Ϫ0.36, SE 0.06, Pϭ9.5ϫ10 Ϫ10 ), and in AGT the minor allele of rs11122587 was associated with increased DBP (replication: Pϭ2.4ϫ10 Ϫ5 ). We sought replication for 6 SNPs where hypertension was the primary trait (Table 3 ). The minor allele of an intron 5 SNP (rs4305) in ACE replicated with all of the cohort associations with increased odds of hypertension (replication: Pϭ7.5ϫ10
). In secondary analysis, this SNP also showed association with increased levels of SBP (Pϭ4.6ϫ10 ). In secondary analyses, the AGT SNP selected for SBP, rs2004776, reached a low P value for DBP (meta-analysis: Pϭ5.0ϫ10 Ϫ8 ). ADRB1 and AGT SNPs were also associated with hypertension, in the same direction as expected based on their BP associations (ADRB1: rs1801253 Pϭ3.3ϫ10 Ϫ4 ; AGT: rs2004776 Pϭ3.7ϫ10 Ϫ7 ). Heterogeneity analyses for ADRB1, AGT, or ACE in the multistudy cohorts (CHARGE and GBPG) or within the full meta-analysis found no evidence for heterogeneity (all I 2 Ͻ0.50). In additional analyses for ADRB1 and AGT, conditioning on the top variant for SBP or DBP, we found no additional SNPs that contributed to these phenotypes after multiple test correction (see the online Data Supplement). Summary results for the 3 replicated genes and 4 promising, 
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nonreplicated genes (ADRB2, CACNA1C, CACNA1A, and SLC12A3) compared with previous results and meta-analyses from the literature are presented in Tables S3 and S4 , respectively (available in the online Data Supplement at http://hyper.ahajournals.org).
Discussion
Within one of the largest genetic studies of BP traits to date, we examined evidence for associations in gene regions encoding protein targets of antihypertensive medications. We conducted a discovery scan in Ͼ29 000 individuals from the CHARGE consortium, with validation of significant results in Ͼ57 000 individuals from GBPG and WGHS. Of note, in previously published GWAS meta-analysis reports from CHARGE and GBPG, 2,7 none of the SNPs that we tested reached genome-wide significance (PϽ5.0ϫ10 Ϫ8 ). Associations at 3 loci in our study (ADRB1, AGT, and ACE) successfully replicated in independent populations.
The ␤-adrenergic receptors (ADRB1 and ADRB2) are targets of a variety of endogenous and pharmacological agonists and antagonists, including epinephrine, norepinephrine, and ␤-blocker drugs, and they mediate important cardiovascular responses, including cardiac contractility and heart rate. A nonsynonymous variant of ADRB1 (rs1801253, Arg389Gly) was reported to alter BP response to ␤-blocker therapy in multiple studies (eg, References 13 and 14) and was also reported to affect outcomes after treatment. [15] [16] [17] However, tests of this variant with baseline BP have generally been conducted in modestly sized samples not drawn from general population cohorts, with conflicting reports about association of the Arg389 allele with increased BP (Table  S3) . 14,16,18 -23 In our survey of 142 SNPs in/near ADRB1, we found the strongest association at rs1801253 with the Gly389 allele being associated with decreased SBP (Pϭ4.7ϫ10 Ϫ10 ) and DBP (Pϭ9.5ϫ10 Ϫ10 ). Our study is consistent with several studies (Table S3) indicating that there is a small reduction in BP associated with Gly389. 16, 19, [21] [22] [23] This result is also consistent with experimental observations that Gly389 acts functionally to reduce basal and agonist-stimulated receptor responses. 24 -26 The renin-angiotensin system plays critical roles in BP regulation, is targeted by multiple drug classes, and has been the subject of previous genetic studies for candidate genes (eg, AGT and ACE). Among 3 AGT SNPs (rs2004776, rs12046196, and rs11122587) associated with BP in CHARGE, rs2004776, in intron 1 (between the AGT 5ЈUTR and exon 1), showed the strongest validation in an independent European ancestry cohort (meta-analysis Pϭ5.0ϫ10 Ϫ8 ). Of note, rs2004776 is in partial LD (r 2 ϭ0.49, HapMap CEU) with a Met235Thr (rs699) that has been widely studied for values for DBP are as follows: CHARGE (ϭ1.05), GBPG (ϭ1.07), and WGHS (ϭ1.06). ␤ reflects the unit change in millimeters of mercury in SBP/DBP or in log odds of hypertension per allele dose. SE indicates SEM. Replicated SNPs are in bold. SBP indicates systolic blood pressure; DBP, diastolic blood pressure; CHARGE, Cohorts for Heart and Aging Research in Genomic Epidemiology; GWAS, genome-wide association study; SNP, single nucleotide polymorphism; GBPG, Global BPgen Consortium; WGHS, Women's Genome Health Study; MAF, minor allele frequency.
*P values have been taken from GWAS results corrected by the genomic control approach. 9 association with hypertension. 27 Previous analyses suggest a role for Met235Thr 27, 28 or other variants affecting AGT function 29, 30 in hypertension, with multiple variants being supported in meta-analyses (Table S3) . 27, 29 In CHARGE, the minor allele of Met235Thr showed nominal association with hypertension (Pϭ0.0011), SBP (Pϭ0.012), and DBP (Pϭ0.0042). These results suggest that Met235Thr may not be the most relevant AGT variant and that there may be other functional alleles to be discovered and characterized. Another important gene within the renin-angiotensin system, ACE, showed significant positive association with hypertension (rs4305; Pϭ3.0ϫ10 Ϫ5 ), and with SBP (Pϭ4.6ϫ10 Ϫ4 ) and DBP (Pϭ6.0ϫ10 Ϫ5 ). ACE genotypes have been studied for association with various traits, including BP and hypertension, where results from a literaturebased meta-analysis indicate no significant effect. 31 A large study of antihypertensive drug response also indicates no genotype-treatment effect. 32 However; most previous studies focused only on the well-known intronic I/D polymorphism (Table S3 ) and lacked detailed information on the genetic architecture of ACE. The importance of this point is emphasized by a recent resequencing study of ACE in blacks that found novel functional variation associated with myocardial infarction in hypertensives. 33 Furthermore, a recent GWAS for ACE enzyme activity found strong association of the minor allele of rs4343 with increased activity in Han Chinese (Pϭ3.0ϫ10 Ϫ25 ). 34 The nonsynonymous SNP rs4343 is in moderate-high LD in Asian and European populations with our replicated BP SNP, rs4305 (HapMap CEU r 2 ϭ0.48; JPT/CHB r 2 ϭ0.80), suggesting a potential common link between the studies. We examined a sample of 944 unrelated individuals in The Framingham Heart Study and found rs4350-I/D is also in modest LD (r 2 ϭ0.55). The effects of variation in ADRB1, AGT, and ACE on BP variation and treatment response were the subject of previous research (Table S3) . Our large study validates their role in BP genetics. The effect sizes of the ADRB1 and AGT variants are on par with variants identified in GWAS for BP, lipids, and similar traits, accounting for only Ϸ0.25% to 0.50% of the variation in BP. 2, 7, 35 These results demonstrate that surveying previous biological candidates in large genetic studies may be a useful approach to identify and replicate additional loci. This observation is consistent with 2 recent surveys of published GWASs that indicate some a priori candidates show true associations. 36, 37 Candidate genes for variation in lipid levels have also been validated in GWASs and shown to have treatment effects. 4, 5, 35 The loci and variants identified here may also influence treatment response, a hypothesis that we did not assess. Our study is limited in that treated and untreated individuals are included, with variable ascertainment of treatment across cohorts. We applied differing treatment adjustments in different cohorts to impute expected baseline effects. Further analysis in CHARGE indicates that ϩ15/10 and ϩ10/5 adjustments generate similar results for BP associations, so this is unlikely to have greatly affected replication (Table S1 and Figures S2 and S3 , available in the online Data Supplement at http://hyper.ahajournals.org). Because treatment of participants in our GWAS was nonrandomized, it is difficult to assess gene-by-treatment interactions without confounding. Prospective studies, or more sophisticated cross-sectional analyses, will be required to determine whether gene variants identified from large GWASs influence treatment outcomes; our results indicate that these could be worthwhile pursuits. Another potential limitation of the study is reliance in WGHS on self-reported BP values. However, past studies indicate that self-report is reasonably reliable in assessment of BP and hypertension (eg, References 38 and 39). Furthermore, we independently found high replication rates for BP GWAS loci in the WGHS. 40 
Perspectives
Our results indicate that candidate genes, with clinical and physiological relevance by virtue of their role as antihypertensive drug targets, harbor true BP-associated variants. Such loci, not identified in previous large GWAS meta-analyses but detected in our drug target gene approach, account for a portion of the unexplained proportion of BP variance. These results suggest that revisiting GWAS scans from the perspective of biological and clinical knowledge may be useful for discovery and validation of new genetic associations. 
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